Philip Berardi profile picture

Contact Information

Philip Berardi, MD, PhD, FRCPC
6137985555
pberardi@toh.on.ca

Philip Berardi

Clinician Investigator, Cancer Therapeutics Program
Ottawa Hospital Research Institute

Research Interests

Hematological Pathology and Transfusion Medicine
Molecular Oncology and Precision Medicine
Gene regulation and oncogenesis
Epigenetics in hematolymphoid neoplasms

Brief Biography

Clinician Investigator in the Cancer Therapeutics Program
Ottawa Hospital Research Institute (OHRI)

Assistant Professor
The Ottawa Hospital / University of Ottawa

Staff Hematopathologist
Division of Anatomical Pathology

Associate Director
Molecular Oncology Diagnostics Laboratory

Section Head
Complex Malignant Hematology DNA Testing Laboratory

Selected Publications

Clarke G, Hannon J, Berardi P, Barr G, Cote J, Fallis R, Alport T, Lane D, Petraszko T, Ochoa G, Goldman M. Resolving variable maternal D typing using serology and genotyping in selected prenatal patients. Transfusion. 2016 Dec;56(12):2980-2985. doi: 10.1111/trf.13798. Epub 2016 Sep 9.

Berardi P, Bessette E, Ng M, Angus N, Lane D, Gariepy L, Pavenski K, Ochoa-Garay G, Cote J, Goldman M. Weak D type 67 in four related Canadian blood donors. Immunohematology. 2015;31(4):159-62.

Padmore R, Berardi P, Erickson K, Desjardins D, Giulivi A, Tokessy M, Neurath D, Saidenberg E. Acute extravascular haemolytic transfusion reaction due to Anti-Kpa antibody missed by electronic crossmatch. Transfusion and Apheresis Science. 2014 Aug 15. S1473-0502(14)00150-5 [Epub ahead of print].

Samiee S, Berardi P, Bouganim N, Vandermeer L, Arnaout A, Mirsky D, Chasen M, Dent S, Caudrelier J, Clemons M. Excision of the primary tumour in patients with metastatic breast cancer: A Clinical Dilemma. Current Oncology. 2012 Aug; 19(4): 270-279.

Feki A, Berardi P, Bellingan G, Major A, Krause K, Petignat P, Zehra R, Pervaiz S, Irminger-Finger I. Dissemination of intraperitoneal ovarian cancer: Discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model. Critical Reviews in Oncology Hematology. 2009 Oct; 72(1):1-9.

Berardi P, Soliman MA, Pastyryeva S, Bonnefin P, Feng X, Colina A, Young D and Riabowol K. ING1a expression increases during replicative senescence and induces a senescent phenotype. Aging Cell. 2008 Dec; 7(6):783-94.

Russell M, Berardi P and Riabowol K. Grow-ING, Age-ING, and Die-ING: ING proteins link cancer, senescence and apoptosis. Experimental Cell Research. 2006 Apr 15; 312(7):951-61. Epub 2006 Mar 3.

Han X, Berardi P, Riabowol K. Chromatin modification and senescence: linkage by tumor suppressors? Rejuvenation Res. 2006 Spring; 9(1):69-76.

Feki A, Jefford C, Berardi P, Krause K and Irminger-Finger I. BARD1 induces apoptosis by catalyzing phosphorylation of p53 by DNA-damage response kinase. Oncogene. 2005 May 26; 24(23):3726-36.

Berardi P, Russell M, El-Osta A and Riabowol K. Functional links between transcription, DNA repair and apoptosis. Cellular and Molecular Life Sciences. 2004 Sept; 61(17):2173-80.

Berardi P, Meyyappan M and Riabowol K. A novel transcriptional inhibitory element differentially regulates the cyclin D1 gene in senescent cells. Journal of Biological Chemistry. 2003 Feb 28; 278(9):7510-9.

Diseases, conditions and populations of interest


Blood cancer; Cancer



Research and clinical approaches


Basic research; Bioinformatics; Biomarkers; Cell therapy; Epigenetics; Epigenetics; Gene expression; Genetics; Genomics; Immunotherapy; Stem cells; Stem cells; Translational research